BioVie Inc. (BIVI)
NASDAQ (CM) NASDAQ (CM) Primary Summary
BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites Transcript
BioVie Inc. (BIVI) Discusses Clinical Updates on Bezisterim and BIV201 for Parkinson's, Alzheimer's, and Ascites Transcript
BioVie: Long COVID trial fully enrolled – ICYMI
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment, marking an important milestone for the biotechnology company as it advances a potential treatment for patients suffering persistent post-COVID symptoms. Speaking with Proactive, CEO Cuong Do said the study enrolled more than 200 long COVID patients with support from major medical institutions including Yale, Mount Sinai, Mayo Clinic and Stanford.
BioVie completes enrollment in Phase 2 Long COVID trial
BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday it has completed enrollment in its ADDRESS-LC Phase 2 clinical trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID, with topline data expected later this summer. The trial, fully funded by a grant from the US Department of War, is testing whether bezisterim can address neurological and neuropsychiatric symptoms associated with Long COVID, including fatigue, cognitive dysfunction, post-exertional malaise and sleep disturbance.
BioVie Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3 | $4 | $4.89 | $0.89 | 22.25% |
BioVie Inc. (BIVI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has BioVie Inc. ever had a stock split?
BioVie Inc. Profile
| Biotechnology Industry | Healthcare Sector | Cuong Viet Do CEO | NASDAQ (CM) Exchange | 09074F504 CUSIP |
| US Country | 14 Employees | - Last Dividend | 7 Jul 2025 Last Split | - IPO Date |
Overview
BioVie Inc. is a clinical stage biopharmaceutical company, operating predominantly within the United States, dedicated to the discovery, development, and eventual commercialization of novel pharmaceutical solutions aimed at treating chronic debilitating conditions. The company, which was initially known as NanoAntibiotics, Inc., underwent a name change to BioVie Inc. in July 2016, marking a significant milestone in its corporate journey since its inception in 2013. With its headquarters located in Carson City, Nevada, BioVie is at the forefront of addressing some of the most pressing medical challenges of the current era through its elaborate pipeline of groundbreaking drugs.
Products and Services
BIV201: This pivotal product has successfully completed a Phase IIa clinical trial and represents BioVie's ambitious efforts in tackling ascites caused by chronic liver cirrhosis. Ascites, an accumulation of fluid in the peritoneal cavity, often signifies advanced liver disease and poses significant treatment challenges. BIV201's progress through the clinical trial phases underscores its potential as a much-needed solution for patients grappling with this debilitating condition.
NE3107: An innovative therapeutic candidate, NE3107 targets the inflammatory extracellular single-regulated kinase pathway, potentially offering relief to patients suffering from neurological disorders. This compound is making strides in the clinical evaluation process, currently undergoing a Phase III clinical trial for the treatment of mild to moderate Alzheimer's disease. Alzheimer's, a progressive neurodegenerative disorder, significantly impacts cognitive function, whereas Parkinson’s disease, another focus of NE3107’s development in a separate Phase 2 clinical trial, affects movement. The dual focus on these distinct yet somewhat related neurological conditions marks NE3107 as a versatile component in BioVie’s product pipeline.
